Carlos O Mendivil1, Jeremy Furtado1, Allyson M Morton1, Liyun Wang1, Frank M Sacks2. 1. From the School of Medicine, Universidad de los Andes, Bogotá, Colombia (C.O.M.); Section of Endocrinology, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia (C.O.M.); Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA (C.O.M., J.F., A.M.M., L.W., F.M.S.); and Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (F.M.S.). 2. From the School of Medicine, Universidad de los Andes, Bogotá, Colombia (C.O.M.); Section of Endocrinology, Hospital Universitario Fundación Santa Fe de Bogotá, Bogotá, Colombia (C.O.M.); Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA (C.O.M., J.F., A.M.M., L.W., F.M.S.); and Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (F.M.S.). fsacks@hsph.harvard.edu.
Abstract
OBJECTIVE: A prevailing concept is that high-density lipoprotein (HDL) is secreted into the systemic circulation as a small mainly discoidal particle, which expands progressively and becomes spherical by uptake and esterification of cellular cholesterol and then contracts by cholesterol ester delivery to the liver, a process known as reverse cholesterol transport, thought to be impaired in people with low HDL cholesterol (HDLc). This metabolic framework has not been established in humans. APPROACH AND RESULTS: We studied the metabolism of apolipoprotein A-I in 4 standard HDL sizes by endogenous isotopic labeling in 6 overweight adults with low HDLc and in 6 adults with normal body weight with high plasma HDLc. Contrary to expectation, HDL was secreted into the circulation in its entire size distribution from very small to very large similarly in both groups. Very small (prebeta) HDL comprised only 8% of total apolipoprotein A-I secretion. Each HDL subfraction circulated mostly within its secreted size range for 1 to 4 days and then was cleared. Enlargement of very small and medium to large and very large HDL and generation of very small from medium HDL were minor metabolic pathways. Prebeta HDL was cleared slower, whereas medium, large, and very large HDL were cleared faster in the low HDLc group. CONCLUSIONS: A new model is proposed from these results in which HDL is metabolized in plasma mainly within several discrete, stable sizes across the common range of HDLc concentrations.
OBJECTIVE: A prevailing concept is that high-density lipoprotein (HDL) is secreted into the systemic circulation as a small mainly discoidal particle, which expands progressively and becomes spherical by uptake and esterification of cellular cholesterol and then contracts by cholesterol ester delivery to the liver, a process known as reverse cholesterol transport, thought to be impaired in people with low HDL cholesterol (HDLc). This metabolic framework has not been established in humans. APPROACH AND RESULTS: We studied the metabolism of apolipoprotein A-I in 4 standard HDL sizes by endogenous isotopic labeling in 6 overweight adults with low HDLc and in 6 adults with normal body weight with high plasma HDLc. Contrary to expectation, HDL was secreted into the circulation in its entire size distribution from very small to very large similarly in both groups. Very small (prebeta) HDL comprised only 8% of total apolipoprotein A-I secretion. Each HDL subfraction circulated mostly within its secreted size range for 1 to 4 days and then was cleared. Enlargement of very small and medium to large and very large HDL and generation of very small from medium HDL were minor metabolic pathways. Prebeta HDL was cleared slower, whereas medium, large, and very large HDL were cleared faster in the low HDLc group. CONCLUSIONS: A new model is proposed from these results in which HDL is metabolized in plasma mainly within several discrete, stable sizes across the common range of HDLc concentrations.
Authors: C J Packard; T Demant; J P Stewart; D Bedford; M J Caslake; G Schwertfeger; A Bedynek; J Shepherd; D Seidel Journal: J Lipid Res Date: 2000-02 Impact factor: 5.922
Authors: Ailing Ji; Joanne M Wroblewski; Lei Cai; Maria C de Beer; Nancy R Webb; Deneys R van der Westhuyzen Journal: J Lipid Res Date: 2011-12-20 Impact factor: 5.922
Authors: Gerald F Watts; P Hugh R Barrett; Juying Ji; Adrian P Serone; Dick C Chan; Kevin D Croft; Franziska Loehrer; Anthony G Johnson Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Robert S Kiss; Dan C McManus; Vivian Franklin; Wei Ling Tan; Andrea McKenzie; Giovanna Chimini; Yves L Marcel Journal: J Biol Chem Date: 2003-01-22 Impact factor: 5.157
Authors: Lijuan Liu; Anna E Bortnick; Margaret Nickel; Padmaja Dhanasekaran; Papasani V Subbaiah; Sissel Lund-Katz; George H Rothblat; Michael C Phillips Journal: J Biol Chem Date: 2003-08-19 Impact factor: 5.157
Authors: Stefan Bilz; Stephan Wagner; Michaela Schmitz; Andrea Bedynek; Ulrich Keller; Thomas Demant Journal: J Lipid Res Date: 2003-10-01 Impact factor: 5.922
Authors: Allison B Andraski; Sasha A Singh; Lang Ho Lee; Hideyuki Higashi; Nathaniel Smith; Bo Zhang; Masanori Aikawa; Frank M Sacks Journal: Arterioscler Thromb Vasc Biol Date: 2019-09-26 Impact factor: 8.311
Authors: Stephen E Henrich; Bong Jin Hong; Jonathan S Rink; SonBinh T Nguyen; C Shad Thaxton Journal: J Am Chem Soc Date: 2019-06-13 Impact factor: 15.419
Authors: Alexina Orsoni; Patrice Thérond; Ricardo Tan; Philippe Giral; Paul Robillard; Anatol Kontush; Peter J Meikle; M John Chapman Journal: J Lipid Res Date: 2016-08-31 Impact factor: 5.922
Authors: Mariko Tani; Katalin V Horvath; Benoit Lamarche; Patrick Couture; John R Burnett; Ernst J Schaefer; Bela F Asztalos Journal: Atherosclerosis Date: 2016-08-20 Impact factor: 5.162